The Life Sciences Report

Other Streetwise Reports

The Gold Report The Energy Report The Life Sciences Report The Mining Report

Today's Featured Company

Tribute Pharmaceuticals Canada Inc. : (TBUFF:OTCQB) Tribute Pharmaceuticals Canada Inc. is a specialty pharmaceutical company that acquires, licenses, develops and sells healthcare products primarily in Canada, with additional global sales through its international partners for its proprietary products. Backed by a management team with deep industry experience and a track record of ramping sales into the hundreds of millions at prior companies, Tribute pursues a high-growth, low-risk strategy of in-licensing, or acquiring products that have already been through costly R&D and received regulatory approvals in other countries. More >

Streetwise Expert Interviews

Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases

To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and sellside analyst. In this, the last of his three interviews with The Life Sciences Report, Selvaraju highlights micro-, small- and mid-cap biotech names with therapies that may add years to patients' lives and liftoff to investor portfolios. (4/22/14) More >

Four Hidden Australian Life Sciences Growth Stocks Revealed: Scott Power

To find undiscovered stories, investors must venture into unfamiliar territory. In this interview with The Life Sciences Report, we go halfway around the world to speak with Scott Power of Morgans Financial Ltd. about companies under coverage in Australia. Power helps investors get comfortable with the idea of putting money into newfound names, and unveils four strong ideas that could invigorate adventuresome portfolios and investors hungering for excitement. (4/17/14) More >

Build Biotech Wealth on Solid Platforms: Grant Zeng

Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular company has the potential to succeed in the fast-moving life sciences industry. In this interview with The Life Sciences Report, Zeng dissects his process and names 10 companies that have survived his exacting examination. (4/17/14) More >

Newsletter Briefs

"ARNI's onapristone could legitimately be considered a pipeline in a single product." (4/22/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More >

"CUR's science is cutting edge, and of a very high quality." (4/22/14) Neuralstem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More >

"If the data from the PRESERVE trial are positive, NEO may be able to enter partnership in the regenerative medicine space." (4/22/14) NeoStem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More >

"DMPI's VAL-083 is a first-in-class small-molecule chemotherapeutic." (4/17/14) DelMar Pharmaceuticals Inc. - The Life Sciences Report Interview with Grant Zeng More >

"SNGX has a very diversified pipeline under development; its Phase 2 trial for SGX924 is going very well." (4/17/14) Soligenix Inc. - The Life Sciences Report Interview with Grant Zeng More >

"There is great potential for NEO to grow in the future." (4/17/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Grant Zeng More >

"RXII has some very important valuation-driving events in progress." (4/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Keith Markey More >

"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum More >

Expert Analysis

"CTH has huge upside, a clear exit strategy and a drug that works." (4/16/14) Cynapsus Therapeutics Inc. - Jason Napodano, Seeking Alpha More >

"NBS' acquisition of California Stem Cell expands its development pipeline of cell therapy products." (4/14/14) NeoStem Inc. - Henry McCusker, Scimitar Equity LLC More >

"CGIX launched a new test to detect mutations in the CALR gene." (4/14/14) Cancer Genetics Inc. - Jerry Isaacson, LifeSci Advisors More >

"The American Heart Journal reported that CYTX's trial showed the procedure was safe, feasible and showed indications of a favorable benefit-to-risk profile." (4/14/14) Cytori Therapeutics Inc. - Henry McCusker, Scimitar Equity LLC More >

"VRS closed a private placement for gross proceeds of $481K." (4/10/14) Verisante Technology Inc. - Brian Marckx, Zacks Small-Cap Research More >

"We are initiating coverage on TBUFF with a Speculative Buy rating." (4/9/14) Tribute Pharmaceuticals Canada Inc. - André Uddin, Mackie Research Capital More >

"BDSI's robust presence at ASAM should raise awareness of Bunavail." (4/7/14) BioDelivery Sciences International Inc. - Charles Duncan, Piper Jaffray & Co. More >

"CTH's recent $25M financing should fund clinical trials for AP-130277." (4/15/14) Cynapsus Therapeutics Inc. - Jerry Isaacson, LifeSci Advisors More >